文献速递其他结缔组织病系统性红斑狼疮

抗磷脂综合征心血管危险因素控制:原发性与SLE相关APS的横断面研究

Cardiovascular risk factor control in antiphospholipid syndrome, and differences between primary and systemic lupus erythematosus-related antiphospholipid syndrome (SURF-SLE and APS project): a cross-sectional study of 1003 individuals from 11 countries.
PubMed 文献 · Lancet Rheumatol · 2025-11-19

这项跨11国17中心的横断面研究纳入1003例APS患者,评估传统心血管危险因素达标情况。结果显示高血压、高脂血症、肥胖和吸烟普遍,个体及复合危险因素控制均不充分;SLE相关APS的高血压和高脂血症患病率高于原发性APS,但原发性APS在戒烟、血压<130/80 mmHg及≥2项危险因素达标方面更差。

要点

  • APS患者高血压41%、高脂血症34%、肥胖32%、当前吸烟19%,个体及复合心血管危险因素控制均不充分。
  • SLE相关APS较原发性APS高血压患病率更高(50% vs 33%,p<0·0001),高脂血症更高(40% vs 30%,p=0·0009)。
  • 原发性APS较SLE相关APS戒烟达标更差(78% vs 84%,p=0·012),血压<130/80 mmHg达标更差(48% vs 57%,p=0·0067)。

核心结论

  • 在这项大型真实世界研究中,APS患者心血管危险因素患病率高且控制欠佳,尤其在心血管风险常被忽视的原发性APS患者中。

研究设计与样本

  • 横断面研究,收集2015年1月1日至2020年1月1日(部分中心因COVID-19疫情延长至2022年)11国17中心APS患者病历数据。
  • 纳入≥18岁且符合修订札幌APS分类标准的患者,共1003例(女性779例[78%],男性224例[22%];1000例中白人662例[66%])。
  • 中位年龄47·0岁(IQR 38·0-57·0),中位病程11·0年(5·0-18·0);原发性APS 539例(54%),SLE相关APS 464例(46%)。
  • 采用Systematic Coronary Risk Evaluation算法评估心血管风险,按欧洲心脏病学会指南评估危险因素达标,拟合未调整和调整的混合效应logistic回归模型。

主要发现

  • 高血压411/1003例(41%),高脂血症344/1003例(34%),肥胖295/919例(32%),当前吸烟186/963例(19%)。
  • SLE相关APS vs 原发性APS:高血压234/464例(50%)vs 177/539例(33%),p<0·0001;高脂血症184/464例(40%)vs 160/539例(30%),p=0·0009。
  • SLE相关APS vs 原发性APS:当前吸烟72/452例(16%)vs 114/511例(22%),p=0·012。
  • 原发性APS vs SLE相关APS:戒烟达标397/511例(78%)vs 380/452例(84%),p=0·012;血压<130/80 mmHg达标246/514例(48%)vs 258/456例(57%),p=0·0067。
  • 年龄和动脉血栓史与达到≥3项或全部4项心血管危险因素目标的 odds 降低相关。

关键数值与推荐

  • 血压目标为<130/80 mmHg;复合目标包括吸烟、BMI、血压、LDL中≥2项达标。
  • 在高和极高心血管风险亚组中,原发性APS较SLE相关APS在戒烟、血压<130/80 mmHg、BMI、LDL、甘油三酯、≥2项及≥3项目标达标方面均更差。

临床怎么用

  • 在APS患者中应关注传统心血管危险因素的高患病率和控制不充分问题,尤其对原发性APS患者需提高心血管风险意识。

局限性

  • 原文未述局限性

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: The European Alliance of Associations for Rheumatology recommendations for cardiovascular risk management highlighted the importance of traditional cardiovascular risk factor control in antiphospholipid syndrome (APS). However, cardiovascular risk factor target attainment in APS and differences between primary APS and systemic lupus erythematosus (SLE)-related APS remain uncertain. METHODS: Cardiovascular risk factor data were collected from medical records of patients in 17 centres from 11 countries between Jan 1, 2015, and Jan 1, 2020 (extended to 2022 for some centres unable to complete the survey by the end of 2020 due to the COVID-19 pandemic), and analysed cross-sectionally. Included patients were 18 years or older and met the revised Sapporo APS classification criteria. Patients who also met the 2012 Systemic Lupus International Collaborating Clinics (SLICC) classification criteria for SLE were classified as having SLE-related APS. Patients with APS in association with systemic autoimmune diseases other than SLE were excluded. Cardiovascular risk was estimated using the Systematic Coronary Risk Evaluation algorithm, and cardiovascular risk factor target attainment was assessed using European Society of Cardiology guidelines. Unadjusted and adjusted mixed effects logistic regression models were fitted. People with lived experience were not involved in the study design. FINDINGS: In total, 1003 patients with APS were included (779 [78%] women and 224 [22%] men; 662 [66%] of 1000 were White), with a median age of 47·0 years (IQR 38·0-57·0) and a median disease duration of 11·0 years (5·0-18·0). 539 (54%) patients had primary APS and 464 (46%) had SLE-related APS. We found a high prevalence of cardiovascular risk factors (hypertension, 411 [41%] of 1003; hyperlipidaemia, 344 [34%] of 1003; obesity, 295 [32%] of 919; current smoking, 186 [19%] of 963) and inadequate individual (blood pressure less than 130/80 mm Hg, BMI, and lipids) and composite cardiovascular risk factor control in all patients. A higher prevalence of hypertension (234 [50%] of 464 vs 177 [33%] of 539; p<0·0001) and hyperlipidaemia (184 [40%] of 464 vs 160 [30%] of 539; p=0·0009) was observed in SLE-related APS versus primary APS, but a lower prevalence of current smoking (72 [16%] of 452 vs 114 [22%] of 511; p=0·012). Patients with primary APS had worse target attainment for smoking cessation (397 [78%] of 511 vs 380 [84%] of 452; p=0·012), blood pressure less than 130/80 mm Hg (246 [48%] of 514 vs 258 [57%] of 456; p=0·0067), and two or more cardiovascular risk factor targets (of smoking, BMI, blood pressure, LDL) than patients with SLE-related APS in the entire group, as well as worse target attainment for smoking cessation, blood pressure less than 130/80 mmHg, BMI, LDL, triglycerides, two or more and three or more targets in the high and very high cardiovascular risk subgroup. Age and arterial thrombosis history were associated with lower odds of attaining three or more or all four cardiovascular risk factor targets. INTERPRETATION: In this large real-world study, high prevalence and suboptimal cardiovascular risk factor control were observed in patients with APS, highlighting the need for increased cardiovascular risk awareness, especially in those with primary APS, whose cardiovascular risk is often overlooked. FUNDING: None.

来源:Lancet Rheumatol,查看原文。版权归原作者所有。

引用

  1. Bolla E, Semb AG, Petri M, et al. Cardiovascular risk factor control in antiphospholipid syndrome, and differences between primary and systemic lupus erythematosus-related antiphospholipid syndrome (SURF-SLE and APS project): a cross-sectional study of 1003 individuals from 11 countries. Lancet Rheumatol. 2025. PMID: 41274305. doi:10.1016/S2665-9913(25)00257-7

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。